MHRA (Medicines & Healthcare Products Regulatory Agency) updates UK situation after Boston extends recall
This article was originally published in Clinica
Executive Summary
UK healthcare providers are to assess the validity of their stocks of Boston Scientific stent systems according to each product's use-by date, so as to correlate it to the manufacturing date, rather than cross-refer to the extensive list of product codes. So advises the Medicines and Healthcare products Regulatory Agency (MHRA), following the US company's August 5 worldwide update of recalls related to its Taxus paclitaxel-eluting stent and Express2 bare-metal stent systems (see this issue, page 16).